RxDoctor Payments Data

Emily Saul, DO

Hematology & Oncology · Columbus, OHNPI 1598050908

Payments from drug & device makers

$2,538in general payments, 2019–2025

Across 26 payments — averaging $97.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Geron Corporation$780
  • Gilead$235
  • Amgen$212
  • Cardinal Health 110 LLC$176
  • Genentech USA, Inc.$171
  • Adaptive Biotechnologies Corporation$160
  • plus $805 from 10 others

What the payments were for

  • Consulting fees$78031%
  • Food & beverage$1,34453%
  • Education$41416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,538 in reported general payments places this provider in the 35th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,590,320
Medicare patients
398
Services billed
92,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide46$633,917
RevlimidLenalidomide36$624,739
BrukinsaZanubrutinib20$299,461
XtandiEnzalutamide20$292,168
OrserduElacestrant Hcl12$278,937
CabometyxCabozantinib S-Malate11$264,547
JakafiRuxolitinib Phosphate13$210,461
KisqaliRibociclib Succinate13$177,993
PromactaEltrombopag Olamine13$167,711
NinlaroIxazomib Citrate13$155,431
EliquisApixaban157$111,811
Everolimus11$62,125
XareltoRivaroxaban52$52,181
Imatinib Mesylate19$44,213
Xtampza ErOxycodone Myristate11$13,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Promacta$22$345,70426 claims
Incyte CorporationJakafi$93$210,46113 claims
Johnson & JohnsonXarelto$137$52,18152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →